share_log

Asymchem Laboratories (Tianjin) Co., Ltd. Recorded A 25% Miss On Revenue: Analysts Are Revisiting Their Models

Asymchem Laboratories (Tianjin) Co., Ltd. Recorded A 25% Miss On Revenue: Analysts Are Revisiting Their Models

Asymchem实验室(天津)有限公司的收入下降了25%:分析师正在重新审视他们的模型
Simply Wall St ·  04/27 20:43

It's been a good week for Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) shareholders, because the company has just released its latest first-quarter results, and the shares gained 5.7% to CN¥80.99. Asymchem Laboratories (Tianjin) reported a serious miss, with revenue of CN¥1.4b falling a huge 25% short of analyst estimates. The bright side is that statutory earnings per share of CN¥6.26 were in line with forecasts. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

对于Asymchem实验室(天津)有限公司(深圳证券交易所:002821)的股东来说,这是美好的一周,因为该公司刚刚发布了最新的第一季度业绩,股价上涨了5.7%,至80.99元人民币。Asymchem Laboratories(天津)报告了严重失误,收入为14亿元人民币,比分析师的预期大幅下降了25%。好的一面是,6.26元人民币的法定每股收益符合预期。对于投资者来说,盈利是一个重要时刻,因为他们可以追踪公司的业绩,查看分析师对明年的预测,看看对公司的情绪是否发生了变化。因此,我们收集了最新的财报后法定共识估计,以了解明年可能会发生什么。

earnings-and-revenue-growth
SZSE:002821 Earnings and Revenue Growth April 28th 2024
SZSE: 002821 收益和收入增长 2024 年 4 月 28 日

Following the recent earnings report, the consensus from 16 analysts covering Asymchem Laboratories (Tianjin) is for revenues of CN¥6.45b in 2024. This implies a noticeable 7.5% decline in revenue compared to the last 12 months. Statutory earnings per share are forecast to plunge 38% to CN¥3.33 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥6.56b and earnings per share (EPS) of CN¥3.88 in 2024. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a real cut to EPS estimates.

继最近的财报之后,涵盖Asymchem实验室(天津)的16位分析师一致认为,2024年的收入为64.5亿元人民币。这意味着与过去12个月相比,收入明显下降了7.5%。预计同期法定每股收益将下降38%,至3.33元人民币。然而,在最新财报公布之前,分析师曾预计2024年的收入为65.6亿元人民币,每股收益(EPS)为3.88元人民币。最新业绩公布后,分析师似乎变得更加看跌。尽管收入预测没有变化,但每股收益的预期确实有所下调。

The average price target fell 13% to CN¥99.88, with reduced earnings forecasts clearly tied to a lower valuation estimate. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Asymchem Laboratories (Tianjin), with the most bullish analyst valuing it at CN¥145 and the most bearish at CN¥61.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

平均目标股价下降了13%,至99.88元人民币,收益预期的下调显然与估值估计值的降低有关。研究分析师的估计范围,评估异常值与平均值的差异程度也可能很有启发性。对Asymchem Laboratories(天津)的看法有所不同,最看涨的分析师将其估值为145元人民币,最看跌的为每股61.00元人民币。这是相当广泛的估计,表明分析师正在预测该业务的各种可能结果。

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 9.8% by the end of 2024. This indicates a significant reduction from annual growth of 33% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 15% per year. It's pretty clear that Asymchem Laboratories (Tianjin)'s revenues are expected to perform substantially worse than the wider industry.

从现在的大局来看,我们可以理解这些预测的方法之一是看看它们如何与过去的业绩和行业增长预期相比较。这些估计表明,收入预计将放缓,预计到2024年底年化下降9.8%。这表明与过去五年的33%的年增长率相比大幅下降。相比之下,我们的数据表明,总体而言,同一行业的其他公司的收入预计每年将增长15%。很明显,Asymchem Laboratories(天津)的收入预计将大大低于整个行业。

The Bottom Line

底线

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Asymchem Laboratories (Tianjin). Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Asymchem Laboratories (Tianjin)'s revenue is expected to perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Asymchem Laboratories (Tianjin)'s future valuation.

最大的担忧是,分析师下调了每股收益预期,这表明Asymchem Laboratories(天津)可能会面临业务不利因素。幸运的是,分析师还重申了他们的收入预期,表明收入符合预期。尽管我们的数据确实表明,Asymchem Laboratories(天津)的收入预计将低于整个行业。共识目标股价大幅下降,分析师似乎没有对最新结果感到放心,这导致对Asymchem Laboratories(天津)未来估值的估计降低。

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Asymchem Laboratories (Tianjin) going out to 2026, and you can see them free on our platform here..

根据这种思路,我们认为该业务的长期前景比明年的收益重要得多。在Simply Wall St,我们有分析师对Asymchem Laboratories(天津)到2026年的全方位估计,你可以在我们的平台上免费看到这些估计。

Plus, you should also learn about the 1 warning sign we've spotted with Asymchem Laboratories (Tianjin) .

此外,您还应该了解我们在Asymchem实验室(天津)发现的1个警告信号。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发